Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Cash & Equivalents (2021 - 2025)

Historic Cash & Equivalents for InMed Pharmaceuticals (INM) over the last 5 years, with Q4 2025 value amounting to $7.0 million.

  • InMed Pharmaceuticals' Cash & Equivalents rose 2537.97% to $7.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $7.0 million, marking a year-over-year increase of 2537.97%. This contributed to the annual value of $11.1 million for FY2025, which is 6854.12% up from last year.
  • InMed Pharmaceuticals' Cash & Equivalents amounted to $7.0 million in Q4 2025, which was up 2537.97% from $9.4 million recorded in Q3 2025.
  • InMed Pharmaceuticals' Cash & Equivalents' 5-year high stood at $15.3 million during Q3 2021, with a 5-year trough of $4.7 million in Q1 2025.
  • Over the past 5 years, InMed Pharmaceuticals' median Cash & Equivalents value was $8.3 million (recorded in 2023), while the average stood at $8.4 million.
  • In the last 5 years, InMed Pharmaceuticals' Cash & Equivalents tumbled by 4144.64% in 2024 and then soared by 6854.12% in 2025.
  • Over the past 5 years, InMed Pharmaceuticals' Cash & Equivalents (Quarter) stood at $11.3 million in 2021, then increased by 1.53% to $11.5 million in 2022, then dropped by 16.74% to $9.5 million in 2023, then tumbled by 41.45% to $5.6 million in 2024, then rose by 25.38% to $7.0 million in 2025.
  • Its Cash & Equivalents stands at $7.0 million for Q4 2025, versus $9.4 million for Q3 2025 and $11.1 million for Q2 2025.